Shetzline Michael
- SEC CIK
- 0001808509
In the past year, 1 open-market sale filing worth $121.6K and no purchases.
Current role at each company
- IRWD Ironwood Pharmaceuticals IncSVP, CMO, Head-Res&Drugas of Mar 12, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $121.6K
- 1 filing
- Net
- −$121.6K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Shetzline Michael as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSaleClass A Common Stock | −15.6K | $3.81 | −$59.3K | −2.8%538.4K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSale | +17.0K | $3.66 | +$62.3K | +3.4%521.4K after | |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSaleClass A Common Stock | −41.3K | $1.76 | −$72.6K | −6.9%554.0K after | |
| May 22, 2024 (view filing) | May 20 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −16.1K | $6.45 | −$104.0K | −3.8%413.7K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −38.6K | $15.24 | −$588.5K | −10.2%340.5K after | |
| May 24, 2023 (view filing) | May 22 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −10.3K | $10.12 | −$104.5K | −3.1%321.1K after | |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −19.3K | $11.36 | −$219.5K | −6.9%261.6K after | 4 lots |
| May 25, 2022 (view filing) | May 23 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −10.6K | $11.50 | −$121.7K | −3.8%266.2K after | 2 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −17.6K | $10.77 | −$189.6K | −8.3%195.4K after | 5 lots |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −13.8K | $11.58 | −$159.5K | −7.0%183.7K after |